Cambridge Investment Research Advisors Inc. Takes Position in Arteris, Inc. (NASDAQ:AIP)

Cambridge Investment Research Advisors Inc. bought a new stake in Arteris, Inc. (NASDAQ:AIP) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,714 shares of the company’s stock, valued at approximately $95,000.

Several other hedge funds and other institutional investors have also made changes to their positions in AIP. GAMMA Investing LLC increased its stake in Arteris by 11,823.3% in the 1st quarter. GAMMA Investing LLC now owns 5,127 shares of the company’s stock worth $350,000 after buying an additional 5,084 shares during the period. PVG Asset Management Corp purchased a new position in Arteris in the 4th quarter worth about $151,000. PharVision Advisers LLC purchased a new position in Arteris in the 4th quarter worth about $173,000. Squarepoint Ops LLC purchased a new position in Arteris in the 4th quarter worth about $160,000. Finally, Two Sigma Advisers LP increased its stake in Arteris by 82.9% in the 4th quarter. Two Sigma Advisers LP now owns 23,600 shares of the company’s stock worth $240,000 after buying an additional 10,700 shares during the period. Hedge funds and other institutional investors own 64.36% of the company’s stock.

Insider Buying and Selling at Arteris

In other Arteris news, CEO K Charles Janac sold 18,620 shares of the stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $10.02, for a total transaction of $186,572.40. Following the transaction, the chief executive officer directly owned 9,889,071 shares in the company, valued at $99,088,491.42. This represents a 0.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Laurent R. Moll sold 4,704 shares of the stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $8.99, for a total transaction of $42,288.96. Following the transaction, the chief operating officer owned 478,761 shares in the company, valued at approximately $4,304,061.39. The trade was a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 121,312 shares of company stock valued at $1,116,563 in the last 90 days. Insiders own 29.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Rosenblatt Securities reaffirmed a “buy” rating and issued a $14.00 price target on shares of Arteris in a research note on Wednesday, May 21st.

Arteris Price Performance

Shares of Arteris stock opened at $9.28 on Tuesday. Arteris, Inc. has a 1 year low of $5.46 and a 1 year high of $12.64. The firm’s 50-day moving average is $8.21 and its two-hundred day moving average is $8.54. The stock has a market cap of $389.56 million, a price-to-earnings ratio of -11.32 and a beta of 1.44.

Arteris Company Profile

Arteris, Inc provides semiconductor interconnect intellectual property (IP) and System-on-Chip (Soc) Integration Automation software solutions (SIA) in the Americas, the Asia Pacific, Europe, and the Middle East. The company develops, licenses, and supports the on-chip interconnect fabric technology used in Soc designs and Network-on-Chip (NoC) interconnect IP.